Financial Performance - For the six months ended 30 June 2024, the unaudited revenue was approximately RMB6,635,688,000, representing a decrease of approximately 3.8% compared to the same period in 2023 (RMB6,897,700,000) [1] - The unaudited net profit attributable to the owners of the Company for the same period was approximately RMB1,107,549,000, reflecting a decrease of approximately 7.5% from RMB1,197,767,000 in 2023 [1] - Gross profit for the six months ended 30 June 2024 was RMB3,376,443,000, compared to RMB3,543,479,000 in 2023, indicating a decline [7] - Profit before taxation for the period was RMB1,366,379,000, down from RMB1,468,339,000 in 2023 [7] - Total comprehensive income for the period was RMB1,170,647,000, compared to RMB1,397,133,000 in the same period of 2023 [9] - Earnings per share (basic) decreased to RMB0.25 from RMB0.27 in the previous year [9] - The company's profit for the period was RMB 1,107,549,000, a decrease from RMB 2,001,906,000 in the previous year, marking a decline of 44.7% [81] Dividends - The Board proposed an interim dividend of RMB0.0919 per share for the six months ended 30 June 2024, an increase from RMB0.0734 per share in the same period of 2023 [2] - The company recognized dividends of RMB 425,093,000 during the period, compared to RMB 356,122,000 in the previous year, marking an increase of 19.4% [19] - The company recognized dividends of RMB 425,093,000 during the period, compared to RMB 687,000,000 in the previous year, indicating a reduction of 38.1% [81] Assets and Liabilities - Non-current assets as of 30 June 2024 amounted to RMB15,001,564,000, slightly down from RMB15,035,940,000 as of 31 December 2023 [11] - As of June 30, 2024, the company's current assets amounted to RMB 19,540,925,000, an increase of 4.9% from RMB 18,634,291,000 as of December 31, 2023 [13] - The net current assets reached RMB 13,581,294,000, up from RMB 11,052,250,000, reflecting a growth of 23% [13] - The total equity attributable to owners of the company increased to RMB 23,075,789,000, a rise of 2.8% from RMB 22,449,121,000 [14] - The total liabilities of the company as of June 30, 2024, were RMB 5,024,718,000, up from RMB 4,546,147,000 at the end of 2023, representing an increase of 10.5% [78] - The non-current liabilities increased to RMB 283,497,000 as of June 30, 2024, from RMB 226,363,000 at the end of 2023, reflecting a rise of 25.3% [78] Cash Flow - The company reported a net cash inflow from operating activities of RMB 1,022,774,000, down from RMB 1,117,151,000 in the previous year, a decline of 8.5% [17] - The net cash outflow from investing activities was RMB 447,281,000, which is an increase in outflow compared to RMB 268,164,000 in 2023 [17] - Cash and cash equivalents at the end of the period were RMB 5,115,081,000, slightly down from RMB 5,167,185,000 at the end of June 2023 [17] - The Group's cash and bank balance as of June 30, 2024, amounted to approximately RMB 7,527,635,000 [122] Segment Performance - Medical device products generated revenue of RMB 3,323,265,000, accounting for approximately 50% of total revenue [41] - The Group's orthopaedic products segment reported revenue of RMB 744,991,000, with a segment profit of RMB 86,662,000 [41] - Interventional products generated revenue of RMB 1,010,341,000, with a segment profit of RMB 32,959,000 [41] - Pharma packaging products achieved revenue of RMB 1,167,605,000, contributing a segment profit of RMB 475,031,000 [41] - Blood management products generated revenue of RMB 420,115,000, with a segment profit of RMB 33,070,000 [41] - The Group's total segment profit for the six months ended June 30, 2024, was RMB 1,256,051,000 [41] Research and Development - Total research and development expenses amounted to approximately RMB301,613,000, representing 4.5% of the Group's revenue [102] - The Group obtained 55 new patents and has 171 patents under application in the PRC, with 56 new product registration certificates received [97] - As of June 30, 2024, the Group had 827 product registration certificates and 996 patents in the PRC [101] Operational Strategy - The Company has formulated a three-pronged operational strategy focusing on "platform-based," "internationalized," and "digitalized" development, supported by "talents" and "innovation" strategies [158] - The Group continues to optimize production and supply chain management to reduce costs and better adapt to market conditions [153] - The Group emphasizes responsible operation and green development, integrating energy conservation and emission reduction initiatives into its production and operations [157] Share Capital and Incentive Scheme - A total of 94,260,000 shares have been issued under the specific mandate, with 129,558,616 shares remaining available for issuance, representing approximately 2.83% of the total issued share capital [181] - The maximum number of shares that may be granted to eligible participants under the Incentive Share Scheme is capped at 0.5% of the issued share capital at the date of grant [181] - The Incentive Share Scheme will be effective for a term of 10 years, expiring on November 16, 2024 [182] - The company aims to attract and retain quality talents through the Incentive Share Scheme, aligning interests between management and employees [177] Customer Base - The Group added 112 hospitals, 29 other medical institutions, and 129 distributors to its PRC customer base, totaling 10,040 customers [107] - The total overseas customers reached 7,501, including 3,269 hospitals and 2,245 distributors [108]
威高股份(01066) - 2024 - 中期财报